VJDementia is committed to improving our service to you

Share this video  

VJDementia is committed to improving our service to you

EAN 2020 | Alzheimer’s disease: what are the challenges when disease-modifying therapies become available?

Paola Barbarino • 26 May 2020
EAN 2020
Alzheimer’s Disease Dementia

Paola Barbarino, CEO, Alzheimer’s Disease International, outlines the challenges to prepare healthcare systems for the diagnosis, treatment, and care of Alzheimer’s disease in a future with disease-modifying therapies. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).

More from Paola Barbarino

5:47
Is the world prepared for dementia?
Paola Barbarino • 26 May 2020
4:20
Dementia care during the COVID-19 pandemic
Paola Barbarino • 26 May 2020
5:16
Post-COVID-19 dementia landscape
Paola Barbarino • 26 May 2020

Related Videos

1:18
The impact of antibodies use on biomedical research
Francesco Antonio Aprile • 31 Mar 2021
3:50
Future perspectives on the study of retina in Alzheimer’s disease
Maya Koronyo-Hamaoui • 31 Mar 2021
3:21
The development of oligomer-specific antibodies and their potential use as a diagnostic tool
Francesco Antonio Aprile • 31 Mar 2021
4:06
Retinal imaging techniques and their applications on Alzheimer’s disease research
Maya Koronyo-Hamaoui • 31 Mar 2021
The content of VJDementia is intended for healthcare professionals